Medizone International, Inc., a research and development company specializing in technologies to decontaminate and sterilize rooms for hospitals, schools, and other critical infrastructure, today outlined plans for its AsepticSureTM ozone based sterilization system. Medizone chairman and CEO, Edwin Marshall, spoke extensively about the technology’s promise, based upon test results, and how the company plans to move forward with its development:
“Our laboratory expansion at Medizone’s dedicated research facility located in Innovation Park at Queen’s University in Kingston, Ontario, Canada has now been completed. Full scale-up testing is scheduled to commence there in January, following the holidays. Our laboratory results continue to produce consistent and repeatable 6 log (99.9999%) reductions for the bacteria of concern in the hospital environment that are considered the main causative agents of hospital acquired infections (HAIs). We are now expecting to replicate those results in full scale room testing.”
“On December 1, 2009 the company announced it had achieved 7.2 log kills for Bacillus subtilis, an internationally accepted surrogate for Anthrax, a kill rate that has subsequently been reconfirmed by additional testing at the company’s laboratory. In combination with our accomplishments with the bacteria of concern regarding HAIs, especially achieving 6.7 log reductions with the spore former Clostridium difficile, to now be able to eradicate Bacillus subtilis has put us squarely in the bioterrorism-countermeasures arena. This is clearly a separate market for the company from the hospital sterilization sector. In this regard, we have revised our business plan since first presenting it at our shareholder meeting on August 26, 2009.”
“Under the revised business plan, in the hospital arena for AsepticSureTM sales and service, Medizone expects to partner with large, well established companies that are already fully embedded in that sector as suppliers, such as medical device manufactures or service companies. The company anticipates that it may partner with several such companies, perhaps covering different geographical markets such as North America, Asia and Europe. The same may prove to be true for the outsourcing of additional manufacturing capacity, we will not necessarily be tied to one manufacture for increased manufacturing capacity. By developing relationships with multiple corporate partners, management believes we will be able to maintain better control over our products and obtain more competitive returns, thereby potentially increasing the share value for our shareholders.”
“While we expect this business plan to guide our future moves, the company has only held preliminary talks with two potential corporate partners in the hospital sector. We are still at an early stage in evaluating the value in potential relationships and have not committed to any corporate relationship as of this time.”
Let us hear your thoughts below: